We are live on
!
Find out more
HEC
Hudson Executive Capital Portfolio holdings
AUM
$151M
1-Year Est. Return
60.14%
This Fund
S&P 500
This Quarter
Est. Return
-10.67%
1 Year Est. Return
+60.14%
3 Year Est. Return
+143.92%
5 Year Est. Return
+104.85%
10 Year Est. Return
+677.02%
AUM
$698M
AUM Growth
-$90M
(-11%)
Cap. Flow
+$10M
Cap. Flow
% of AUM
1.43%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
9
New
–
Increased
2
Reduced
–
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AKYA
Akoya BioSciences
AKYA
|
+$16.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
eHealth
EHTH
|
+$7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 72.33% |
| 2 | Healthcare | 11.59% |
| 3 | Technology | 6.42% |
Similar funds
SHF
CCM
DIG
BDS
MWA
WBCM
CAM
BA
Hudson Executive Capital's Q3 2022 Portfolio in Review
As of Q3 2022, Hudson Executive Capital held 9 positions worth $698M, down 11% from $788M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Hudson Executive Capital's Q3 2022 filing shows 2 increased and 1 closed positions. The largest sale was eHealth, an estimated $7M.
By sector, the portfolio is most concentrated in Financials at 72% of assets, down from 75% a quarter earlier, followed by Healthcare and Technology.
- Hudson Executive Capital added most to Akoya BioSciences in Q3 2022, an estimated $16.5M increase.
- Hudson Executive Capital fully exited eHealth in Q3 2022, selling an estimated $7M.
- Hudson Executive Capital's ten largest holdings make up 100% of its $698M portfolio in Q3 2022.
- Hudson Executive Capital opened 0 new positions and closed 1 in Q3 2022.
- Hudson Executive Capital's portfolio value fell 11% quarter-over-quarter to $698M.
Based on Hudson Executive Capital's 13F filing for Q3 2022, filed 14 Nov 2022.